Home / Market News / $TEM
benzinga Corporate Catalyst Impact 65/100 ● positive

Tempus AI To Present Results From Study Evaluating AI-Enabled Pre-Screening Panel For Patients With Advanced Non-Small Cell Lung Cancer, At ESMO Congress 2026

Oct 19, 2026, 12:37 PM UTC · Primary ticker $TEM

Tempus AI announced positive results from a study presented at ESMO 2026, demonstrating its AI-enabled pre-screening panel for advanced non-small cell lung cancer (NSCLC) achieved over 80% sensitivity across 12 biomarkers. This technology, developed in collaboration with Pfizer, aims to improve diagnostic efficiency and patient access to personalized therapies, potentially streamlining biomarker testing workflows.

Tempus AI disclosed positive results from a study evaluating its AI-enabled pre-screening panel for advanced NSCLC, presented at ESMO 2026. The panel showed greater than 80% sensitivity across 12 biomarkers, which is significant because it could help clinicians prioritize diagnostic testing, accelerate access to personalized therapies, and preserve limited tissue samples. This is a positive development for Tempus AI, as it validates their technology and strengthens their position in AI-driven diagnostics. For Pfizer, as a collaboration partner, it reinforces their commitment to addressing diagnostic barriers in oncology. In the short term, this could boost investor confidence in Tempus AI's technological capabilities. Long-term, successful development and adoption of this tool could lead to increased revenue streams and market share in the precision oncology space, offering an opportunity for traders to consider Tempus AI's growth potential.

$TEM positive Successful study results for key product
$PFE positive Collaboration partner in successful study
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.